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Background
Nilotinib is a second-generation tyrosine kinase inhibitor with significant efficacy as first- or
second-line treatment in patients with chronic myeloid leukemia. Despite preclinical evidence
indicating a risk of prolongation of the QT interval, which was confirmed in clinical trials,
detailed information on nilotinib’s cardiac safety profile is lacking.
Design and Methods
Here, we retrospectively assessed cardiovascular risk factors in 81 patients who were being or
had previously been treated with nilotinib therapy and evaluated cardiovascular parameters by
longitudinal monitoring of the QT interval and left ventricular ejection fraction. Detailed infor-
mation on the occurrence and management of defined cardiac adverse events was extracted.
Results
The median duration of nilotinib therapy was 26 months (range, 1–72). The median QT interval
at baseline was 413 msec (range, 368–499 msec). During follow-up, the median QT was not sig-
nificantly different from the baseline value at any time-point. Sixteen of 81 patients (20%) had
new electrocardiographic changes. Cardiac function, as assessed by measurement of left ven-
tricular ejection fraction, did not change significantly from baseline at any time-point. During a
median follow-up of 44 months (range, 2–73), seven patients (9%), all of whom had received
prior imatinib therapy, developed 11 clinical cardiac adverse events requiring treatment. The
median time from the start of nilotinib therapy to an event was 14.5 months (range, 2–68). Five
of seven patients were able to continue nilotinib therapy with only one brief interruption.
Conclusions
Whereas new electrocardiographic abnormalities were recorded in 20% of all patients and
some of them developed severe or even life-threatening coronary artery disease, QT prolonga-
tion, changes in left ventricular ejection fraction, and clinical cardiac adverse events were
uncommon in patients treated with nilotinib.
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ABSTRACT
Introduction
The pathogenetic role of the BCR-ABLp210 tyrosine kinase
resulting from the reciprocal translocation t(9;22)(q34;q11)
and its gene product BCR-ABL1 in chronic myeloid
leukemia (CML) led to the development of imatinib mesy-
late1 (Novartis Pharmaceuticals Corporation, East Hanover,
NJ, USA). The first small molecule tyrosine kinase inhibitor
(TKI) to be approved, imatinib mesylate additionally targets
c-Kit and PDGFR-α and -b and is now the standard of care
in patients with CML,2 a disease which naturally progresses
from a chronic phase to an accelerated phase and ultimately
to a fatal blast crisis.3 However, because of problems of
intolerance and resistance, the latter resulting from specific
point mutations in the kinase domain of ABL,4 several sec-
ond-generation TKI with increased efficacy and specificity
have been developed.5
Nilotinib (Novartis Pharmaceuticals Corporation), for-
merly AMN107, is an orally active aminopyrimidine-deriv-
ative based on imatinib mesylate with increased selectivity
and inhibitory potency against wild-type BCR-ABL1 and
most imatinib-resistance conferring mutations.6
Considerable clinical efficacy in imatinib-intolerant or –
resistant patients led to nilotinib’s approval for use after the
failure of imatinib treatment.7,8 Subsequently, the ENESTnd
trial showed that nilotinib is superior to imatinib in terms of
cytogenetic and molecular remission rates and rates of dis-
ease progression in newly diagnosed patients.9 Nilotinib
has, therefore, additionally been approved as first-line ther-
apy for patients with CML in chronic phase by the Food
and Drug Administration and the European Medicines
Agency.
However, preclinical safety studies indicated that nilo-
tinib may have cardiac side effects.10 In vitro, cardiac electro-
physiological investigations utilizing the hERG channel and
the isolated rabbit heart assay revealed preclinical signs of
QT prolongation10 but without evidence of cytotoxicity in
neonatal rat ventricular myocytes in vitro or overt cardiovas-
cular pathology or heart failure in vivo.11 In an exploratory
analysis of patients treated within a phase I trial, the cor-
rected QT interval by Fridericia’s formula (QTcF) increased
by 5 to 15 msec.12 Among the 119 patients, two had adverse
cardiac events associated with nilotinib, including one who
developed a pericardial effusion and atrial fibrillation. In
addition, one unexplained sudden death was reported.
Nilotinib carries a Food and Drug Association boxed warn-
ing on possible life-threatening heart problems that may
lead to an irregular heartbeat and possible sudden death.
Therefore, caution in patients with significant cardiac dis-
ease or at risk of having or developing prolongation of
QTcF, correction of low potassium or magnesium levels and
careful monitoring for cardiac events are advised.
As the clinical significance of cardiac side effects of nilo-
tinib is unknown and this may prohibit access of a number
of patients to a highly active drug, we retrospectively ana-
lyzed subclinical and clinical cardiac parameters in patients
treated with nilotinib.
Design and Methods
Patients
All patients at the Department of Hematology and Oncology of
the Charité - Universitätsmedizin Berlin, Campus Virchow-
Klinikum, who were being or had previously been treated with
nilotinib between November 2004 and June 2011 were retrospec-
tively studied for this safety analysis. Nilotinib was administered
as therapy for CML (n=77), for acute lymphoblastic leukemia
(n=2), hypereosinophilic syndrome (n=1) or systemic mastocytosis
(n=1) at a starting daily dose of 400 mg BID orally. As per prescrip-
tion, nilotinib had to be taken after at least 2 hours of fasting. Most
patients were treated within clinical trials (Clinicaltrials.gov:
NCT00109707, NCT00471497, and NCT00905593). All trials
were conducted in accordance with the applicable regulatory
requirements. Patients gave their written informed consent to par-
ticipation in a clinical trial or retrospective analysis of their data. All
procedures were followed in accordance with the Helsinki
Declaration and were approved by the local ethics committee.
Patients were excluded from the trial if they had known uncon-
trolled or medically significant cardiac disease, a left ventricular
ejection fraction (LVEF) <45%, or a QTcF interval >450 msec.
Evaluation of patients
Patients were followed regularly at intervals of 3 to 6 months, as
clinically indicated. Cardiovascular risk factors, body mass index,
and World Health Organization/Eastern Cooperative Oncology
Group (WHO/ECOG), New York Heart Association and Canadian
Cardiovascular Society scores were determined retrospectively
from the patients’ charts and case report forms of clinical trials.
Cardiovascular evaluation
In addition to standard biochemical and hematologic parame-
ters, a baseline 12-lead electrocardiogram and echocardiography
were performed in all patients. A LVEF ≥55% was considered nor-
mal. LVEF values of 41-54% and 26-40% defined mild and moder-
ate left ventricular dysfunction, respectively. Specific cardiovascu-
lar biochemical parameters (creatine kinase-MB or troponin T)
were analyzed only in patients with cardiac events. Every 3 to 6
months, longitudinal cardiac monitoring was conducted for QT
prolongation via electrocardiograms and for heart failure/systolic
dysfunction via echocardiograms. Assessment of prolongation of
the QTc interval was based on the LQTS diagnostic score.13 The
QTc interval was calculated using different methods including
Bazett’s formula and Fridericia’s formula, but the latter was used to
ensure compatibility with previous studies. The 12-lead electrocar-
diograms and echocardiograms were performed, analyzed or
supervised in-house by board-certified cardiologists.
Definition of cardiac events
A cardiac adverse event was defined as the occurrence of a
symptomatic arrhythmia that required treatment, syncope, new
left ventricular dysfunction, acute coronary syndrome including
angina pectoris and myocardial infarction, and sudden death. In
patients who developed cardiac symptoms during nilotinib thera-
py, changes in electrocardiograms were analyzed, and the patients
underwent echocardiography. The initiation and type of cardiac
treatment were based on the clinical findings. Coronary angiogra-
phy was performed when indicated, according to the guidelines of
the European Society of Cardiology.14,15 Electrocardiograms,
echocardiograms and chest X-rays were conducted routinely
before treatment and as clinically indicated during the follow-up.
Statistical analysis
A descriptive statistical analysis was performed using the one-
way ANOVA-test with Dunnett’s post-test when appropriate.
Overall survival was measured from the start of nilotinib therapy
to death, and event-free survival (EFS) was measured from the start
of nilotinib therapy to any of the following events while on thera-
py: death from any cause, cardiac adverse event, discontinuation of
therapy because of toxicity or lack of efficacy, loss of complete
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hematologic response, loss of complete cytogenetic response, or
progression to accelerated or blast phase disease. A P value less
than 0.05 was considered statistically significant. All tests were
two-sided.
Results
Patients’ characteristics
Eighty-one patients [44 males (54.3%)], with a median
age of 57 years (range, 25–85) were studied and followed up
for a median of 44 months (range, 2–73). The median dis-
ease duration was 36 months (range, 1–180). Patients
received nilotinib either as part of clinical trials (n=50, 62%)
or as per prescription (n=31, 38%). All patients had a
WHO/ECOG score of 2 or better and 61 patients (75%) had
a WHO/ECOG score of 0. Previous therapies included pri-
marily imatinib mesylate in 66 patients (81%), and interfer-
on-α in 22 (27%).
At baseline, the documented cardiovascular risk factors in
the 81 patients included type 2 diabetes mellitus in 11
patients (14%), untreated hypertension in two (2%), con-
trolled hypertension in 26 (32%), current or former nicotine
abuse in three (4%), grade 1 obesity in seven (9%), and
grade 2 obesity in two (2%). Overall, 41 of 81 patients
(51%) had one or more cardiovascular risk factors. A med-
ical history of cardiovascular disease, including coronary
artery disease and arrhythmia, was each present in six (7%)
patients. Four of six patients with coronary artery disease
had had a myocardial infarction prior to the nilotinib thera-
py. Clinically, only one patient had a Canadian
Cardiovascular Society score of 1, and one patient each had
New York Heart Association (NYHA) grade 1 or 2 heart fail-
ure. Systolic and diastolic dysfunction were present in three
(4%) and 32 (40%) patients, respectively.
Patients treated within clinical trials had a significantly
shorter median disease duration (15 months), but longer
treatment with nilotinib (37 months) than patients who
received nilotinib as per prescription (60 and 8 months,
respectively). No other baseline characteristic differed sig-
nificantly between these two groups (data not shown).
Cardiovascular monitoring 
At baseline, 26 patients (32%) had electrocardiographic
changes including rhythm abnormalities in six (7%), con-
duction disturbances in 12 (15%), ST segment changes in
two (2%), T wave changes in four (5%), and QTc prolonga-
tion in four (5%) patients. Of note, two patients had con-
duction disturbances and QTc prolongation concomitantly.
Under treatment, 12 of these 26 patients had resolution of
their electrocardiographic changes and 16 of all 81 patients
(20%) developed new changes including rhythm abnormal-
ities in 4 (5%), conduction disturbances in one (1%), ST seg-
ment changes in two (2%), T wave changes in two (2%),
and QTc prolongation in nine (11%) patients.
Overall, the median QTcF interval at baseline was 413
msec (range, 368–499 msec). An increase of >30 msec or
>60 msec occurred in 18 (22%) and two (2%) patients,
respectively. No patients had an absolute QTcF interval
>500 msec at any time during the observational period.
During follow-up, the median QTcF was never higher than
420 msec (range, 406–420 msec) (Figure 1A).
At least one LVEF measurement was available during fol-
low-up for 46 of the 81 patients (57%). The median base-
line LVEF was 55%. After 1, 3, 6 and 12 months of follow-
up and more than 1 year later or at end of study there were
no significant differences from baseline (Figure 1B). LVEF
did not decrease below 50% in any patient, but seven
patients had echocardiographic evidence of new diastolic
dysfunction without clinical symptoms.
Clinical cardiac events and management
Overall, seven patients (9%) developed 11 clinical cardiac
Cardiac safety of nilotinib
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Table 1. Patients’ characteristics.
Characteristics                                                     Total number = 81
Male/female, n.                                                                               44/37
Median n. (years, range)                                                        57 (25-85)
Median follow-up (months, range)                                       44 (2-73)
Disease characteristics                                                                    
CML-CP (%)                                                                                61 (75)
CML-AP (%)                                                                                   3 (4)
CML-BP (%)                                                                                13 (16)
Acute lymphoblastic leukemia (%)                                          2 (2)
Hypereosinophilic syndrome (%)                                            1 (1)
Systemic mastocytosis (%)                                                       1 (1)
Median disease duration (months, range)                        36 (1-180)
Median duration on nilotinib (months, range)                  31 (1-73)
Previous therapies                                                                             
None (%)                                                                                       2 (2)
1 (%)                                                                                             23 (28)
2 (%)                                                                                             31 (38)
3 (%)                                                                                             25 (31)
Imatinib (%)                                                                                66 (81)
Interferon-α (%)                                                                       22 (27)
Cardiovascular risk factors                                                              
None (%)                                                                                     40 (49)
1 (%)                                                                                             18 (22)
2 (%)                                                                                             12 (15)
≥3 (%)                                                                                          11 (14)
Untreated hypertension (%)                                                     2 (2)
Controlled hypertension (%)                                                  26 (32)
Hypercholesterolemia (%)                                                        7 (9)
Hypertriglyceridemia (%)                                                          2 (2)
Diabetes mellitus (%)                                                              11 (14)
Current nicotine abuse (%)                                                      1 (1)
Former nicotine abuse (%)                                                       2 (2)
Preobesity (BMI 25-29,5 kg/m2) (%)                                      16 (20)
Grade 1 obesity in (BMI 30-34,9 kg/m2) (%)                          7 (9)
Grade 2 obesity (BMI 35-39,8 kg/m2) (%)                               2 (2)
Cardiovascular disease                                                                     
Coronary artery disease (%)                                                     6 (7)
Arrhythmia1 (%)                                                                            6 (7)
Cardiomyopathy (%)                                                                    1 (1)
Myocardial infarction (%)                                                          4 (5)
Canadian Cardiovascular Society score                                        
0 (%)                                                                                             80 (99)
1 (%)                                                                                               1 (1)
New York Heart Association class                                                 
0 (%)                                                                                             79 (98)
1 (%)                                                                                               1 (1)
2 (%)                                                                                               1 (1)
Left ventricular ejection fraction                                                   
Normal (≥ 55 %) (%)                                                                78 (96)
54-41 % (%)                                                                                   2 (2)
40-26 % (%)                                                                                   1 (1)
1Atrial fibrillation in one patient, atrial premature complexes in two patients, and ventric-
ular premature complexes in three.
adverse events that required treatment (Table 2), of whom
three received nilotinib as per prescription. One event
occurred immediately prior to the start of nilotinib. The
median time from the start of nilotinib therapy to the ten
events that occurred during or after nilotinib exposure was
14.5 months (range, 2–68).
The median age of the seven patients who had cardiac
events was 63 years (range, 61–73), and their median dis-
ease duration was 132 months (range, 72–156). None, one,
two, or three cardiovascular risk factors were present in
one, one, two, and three patients, respectively. Two
patients had had a myocardial infarction prior to nilotinib
treatment and one patient had a reduced LVEF, whereas
four of six patients with a previous medical history of coro-
t.D. Kim et al.
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Table 2. Individual results of patients who experienced a cardiac event.
Patient Age Disease Previous Remission Baseline
(years) duration therapies status1 Cardiovascular Cardiovascular CCS NYHA LVEF Diastolic ECG QTcF
(months) risk factors disease class (%) dysfunction change (msec)
#1 63 156 imatinib, CHR controlled hypertension, 0 0 >55 no no 392
interferon diabetes mellitus, 
hypercholesterolemia
#2 63 72 imatinib, CP hypercholesterolemia, myocardial 1 1 >55 yes no 420
cytarabine hypertriglyceridemia infarction
#3 65 132 imatinib, CCyR 0 0 50 - 41 no conduction 440
interferon disturbance
#4 73 84 imatinib, CHR controlled myocardial 0 0 >55 no no 421
interferon hypertension infarction
#5 69 72 imatinib, CHR controlled hypertension, 0 0 >55 no conduction 408
interferon preobesity, hypercholesterolemia disturbance
#6 61 144 imatinib, MCyR controlled hypertension, 0 0 >55 yes no 408
cytarabine pre-obesity
#7 63 132 imatinib MCyR Controlled hypertension, 0 0 >55 no no 455
pre-obesity, diabetes mellitus
Patient Cardiac Event Outcome
Type Timepoint Management Nilotinib
#1 myocardial infarction month 6 conservative interrupted for 3 weeks, alive at 72 months
then continued at same dose
#2 ACS months 35, 64, and 68 coronary angiography continued at same dose alive at 73 months
with intervention
#3 ACS months 0 and 42 coronary angiography N/A3 alive at 46 months
with intervention
#4 myocardial infarction month 10 N/A N/A dead
#5 atrial fibrillation month 2 conservative continued at same dose alive at 73 months
#6 ACS months 36 coronary angiography with continued at same dose alive at 63 months
intervention
#7 ACS, vasospastic angina pectoris months 7 and 19 coronary angiography without continued at same dose4 alive at 52 months
intervention
1at start of nilotinib. 2 before and 1 month after stopping of nilotinib. 3stopped 1 month before event after 3 months of treatment, dasatinib since month 3, currently receiving imatinib.
4dasatinib since month 31, currently receiving ponatinib; CHR: complete hematologic remission; CP: chronic phase; CCyR: complete cytogenetic response; MCyR: major cytogenetic
response; ACS: acute coronary syndrome.
Figure 1. (A) Duration
of QTcF intervals and
(B) quantitative left
ventricular ejection
fractions (LVEF) at
baseline, after 1, 3, 6,
and 12 months and
more than 1 year or
at the end of study
(EOS).
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nary artery disease had no cardiac events during follow-up.
All patients had previously received imatinib therapy.
Six patients had an acute coronary syndrome including
two with a myocardial infarction, of which one was lethal,
and one had newly developed atrial fibrillation.
Management included coronary angiography with inter-
vention in three patients. With the exception of one patient
who developed an acute coronary syndrome after cessation
of nilotinib and one patient who died of myocardial infarc-
tion, all other patients were able to continue nilotinib ther-
apy with only one brief interruption for 3 weeks.
Clinical outcome
The median duration of nilotinib therapy in the entire
population was 26 months (range, 1–72) for a total exposure
of 187 patient-years. There were 48 events, including dis-
ease progression (n=12), cardiac adverse events (n=7), and
deaths (n=10), including one due to myocardial infarction in
a 73-year old male patient, but no confirmed cases of sud-
den death. There was no evidence of cumulative toxicity,
i.e. an increase of adverse events with longer exposure.
Event-free survival rates at 3 and 5 years were 46% and
32%, respectively; the overall survival rates at 3 and 5 years
were 88% and 87%, respectively.
Discussion
It is well-known that some anticancer drugs are car-
diotoxic and the importance of this is being increasingly
recognized.16-18 In addition to sharing risk factors, the aging
of the general population in developed countries makes it
more probable that a patient has both cancer and cardiovas-
cular disease, which may present a considerable therapeutic
challenge and has a significant impact on the overall prog-
nosis and survival of cancer patients. Manifestations range
from asymptomatic QT prolongation to reduction in LVEF,
symptomatic congestive heart failure, acute coronary syn-
dromes with myocardial infarction and sudden death.
However, there are currently no standardized definitions,
which has precluded direct comparisons of various studies
and the establishment of universally accepted guidelines or
recommendations. Mechanisms of toxicity to the cardio-
vascular system include direct damage to cardiomyocytes
or inflammation of the pericardium, promotion of blood
clotting in the vessels, and through induction of hyperten-
sion.16
TKI, although originally considered to be less toxic and
better tolerated than other drugs, may also induce cardiac
side effects.19-21 Toxicity may result from inhibition of the
intended target that is expressed in the heart and the vascu-
lature, e.g. on-target toxicity, or inhibition of alternative tar-
gets through limited selectivity, e.g. off-target toxicity.22
Previous reports described cardiotoxicity resulting from
therapy with sunitinib,23,24 sorafinib,24 and imatinib mesy-
late.25 Although the clinical occurrence and/or significance
of the latter are being disputed,26-33 reengineering efforts
have been undertaken to alleviate the problem.34 More
recently, QTc prolongation and myocardial infarction relat-
ed to dasatinib therapy have been reported.35 The generally
low incidence of cardiotoxicity from TKI therapy argues
against a class effect. However, with increasing therapeutic
success long-term follow-up needs to confirm the lack of
late detrimental effects. Recent data related to possible
increases in peripheral arterial occlusive disease under treat-
ment with nilotinib36-38 and pulmonary arterial hypertension
under treatment with dasatinib39 have heightened aware-
ness on the need to monitor carefully for relatively rare tox-
icities after approval of a new drug. Our experience has, so
far, raised the possibility of an increase of severe vascular
events in patients with CML receiving nilotinib therapy,38
necessitating the prospective evaluation of this risk.
Targeted therapies have a well-described effect on the
QT interval40 with QT prolongation known to increase the
risk of malignant cardiac arrhythmias, such as torsade de
pointes, and sudden cardiac death.41 Among patients with
long QT syndrome, the risk of a first cardiac event increases
with a QTc interval >447 msec (RR 1.6 compared to QTc
<446 msec) and >470 msec (RR 5.3). The highest risk is
found when QTc is prolonged to more than 498 msec (RR
8.36 compared to QTc <498 msec).42,43 There is preclinical
evidence of a concentration-dependent effect of nilotinib on
cardial ventricular repolarization.10 In clinical studies,
changes of the QTcF interval from baseline were in the
range of 5 to 15 msec, between 2.5 and 4% of patients had
increases of QTcF of more than 60 msec, and in only study
was an incidence of 1.2% of QTcF intervals >500 msec
reported.7-9,12 In line with these studies, in our cohort no
patient had an absolute QTcF interval >500 msec and 2% of
patients had an increase of QTcF of more than 60 msec.
With a median follow-up of 44 months there were no sig-
nificant changes in QTcF intervals from baseline. However,
20% of patients developed new electrocardiographic
changes that were asymptomatic and clinically irrelevant
with the exception atrial fibrillation in one patient.
Measurement of the LVEF is the most common radiolog-
ical method used to screen for toxic effects on the heart.44
However, its low sensitivity for early prediction of car-
diomyopathy limits its usefulness and diastolic measure-
ments, including the E/A ratio (peak early atrial velocity
divided by peak late atrial velocity) and more recent tech-
niques such as tissue velocity imaging of early diastole,
strain, and strain rate, may be more sensitive to early
changes in cardiac function. In our cohort, there was no sig-
nificant decline in LVEF at any time-point, excluding cases
of overt cardiotoxicity. However, new diastolic dysfunction
was seen in seven patients indicating potential subtle car-
diac changes. Since the diagnosis is examiner-dependent
and there are no standardized tests, the clinical significance
remains unclear.
Cardiac safety of nilotinib
haematologica | 2012; 97(6) 887
Figure 2. Event-free and overall survival for the entire cohort of
patients receiving nilotinib.
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Seven patients had cardiac events that occurred at a medi-
an of 14.5 months after initiation of nilotinib therapy. With
the exception of one case of fatal myocardial infarction, all
events could be managed as clinically indicated without
necessitating significant changes to the continued nilotinib
therapy. In addition, nilotinib does not seem to have a neg-
ative long-term impact. With several confounding factors
involved in these patients, a direct relationship between the
cardiac events and nilotinib cannot be either proven or
excluded. It should be noted that these seven patients were
older and had a longer disease duration compared to the
entire study population. The occurrence of cardiac events
may, therefore, merely reflect cardiovascular disease of the
elderly population and may not be a direct effect of TKI
therapy which would be supported by the lack of overt car-
diotoxicity in vitro and in vivo.11 However, nilotinib may add
to established cardiovascular risk factors or other comor-
bidities either by direct vascular effects, e.g. through inter-
action with discoidin domain receptor 1 (DDR1), or by
metabolic effects, e.g. through increased fasting glucose lev-
els, as has been described for the development of peripheral
arterial occlusive disease.36,45
There are several strategies to prevent or address clinical-
ly relevant cardiovascular toxicity. Only a subgroup of treat-
ed patients will develop relevant cardiac damage and
screening may allow the early identification of those at
increased risk.44 A cardiovascular examination, together
with a thorough personal and family history, can evaluate
the patient at baseline, whereas careful monitoring allows
detection of changes after initiation of treatment. However,
the optimal method has not been established.
Echocardiography, electrocardiography, and the determina-
tion of biomarkers, notably, cardiac troponins and natriuret-
ic peptides46 have distinct advantages and disadvantages.44
Susceptibility to cardiotoxicity is clearly multifactorial and
given the low incidence of cardiovascular events, the deter-
mination of risk factors was not possible. In addition, there
is no information about disease-related or -unrelated car-
diac morbidity in patients with CML. The influence of pre-
vious therapies, e.g. interferon-α or TKI, on cardiotoxicity is
hard to discern, although it should be noted that all patients
with an event had previously received imatinib mesylate.
These patients may benefit particularly from cardiovascular
screening before initiation with nilotinib, although the
anticipated wider use of second-generation TKI as first-line
treatment may lead to a decrease of this population.
Currently, prophylactic medication based on treatment
with nilotinib alone does not seem to be justified. As
comorbidities may significantly influence the occurrence of
cardiac and vascular adverse events under second-genera-
tion TKI, including nilotinib,36,45 a high degree of awareness
is mandatory during the follow-up, since comorbidities
may not be present at the onset of nilotinib therapy and
may only develop over time with long-term treatment. As
for the presence of specific BCR-ABL mutations, knowl-
edge about substance-specific side effects may influence
treatment decisions substantially.45,47
Based on our own experience and published data, Table 3
presents a list of parameters that can be reasonably moni-
tored during the follow-up of patients under nilotinib.
In conclusion, whereas new electrocardiographic abnor-
malities were recorded in 20% of all patients and some of
them developed severe or even life-threatening coronary
artery disease, QT prolongation, changes in LVEF, and clini-
cal cardiac adverse events were uncommon in patients treat-
ed with nilotinib and seldom led to treatment discontinua-
tion. There was no cumulative effect of nilotinib exposure
indicating the cardiac safety of this TKI. Therefore, the data
indicate the need to adhere to current practice guidelines for
monitoring patients with CML who are receiving TKI ther-
apy. Important future questions are whether TKI therapy
can be discontinued in patients with CML48,49 and whether
the period of TKI therapy prior to discontinuation can be
sufficiently brief to avoid or reduce cardiac or other vascular
adverse events, especially in those with risk factors.
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Table 3. Recommendations for the assessment of relevant comorbidi-
ties and non-hematologic adverse events at baseline and during the
follow-up of patients treated with nilotinib. In addition, all parameters
should be evaluated if clinically indicated.
Parameter                       At baseline      During         Comments
                                                              follow-up1        
Electrocardiogram                       X                      X                 
Echocardiogram                           X                                          
Ankle-brachial index (ABI)        X                      X                 
Arterial ultrasound                                               X                 if ABI <1
Thyroid-stimulating hormone   X                      X                 
Pancreatic enzymes                     X                      X                 
Total bilirubin                                X                      X                 
Fasting glucose                             X                      X                 
HbA1c                                              X                      X                 if fasting glucose
                                                                                                       elevated
Oral glucose tolerance test       X                      X                 if fasting glucose
                                                                                                       elevated
1Every 3 to 6 months; HbA1c: glycated hemoglobin.
References
1. Druker BJ. Translation of the Philadelphia
chromosome into therapy for CML. Blood.
2008;112(13):4808-17.
2. Baccarani M, Cortes J, Pane F, Niederwieser
D, Saglio G, Apperley J, et al. Chronic
myeloid leukemia: an update of concepts
and management recommendations of
European LeukemiaNet. J Clin Oncol. 2009;
27(35):6041-51.
3. Hehlmann R, Hochhaus A, Baccarani M.
Chronic myeloid leukaemia. Lancet. 2007;
370(9584):342-50.
4. Apperley JF. Part I: mechanisms of resistance
to imatinib in chronic myeloid leukaemia.
Lancet Oncol. 2007;8(11):1018-29.
5. Weisberg E, Manley PW, Cowan-Jacob
SW, Hochhaus A, Griffin JD. Second gener-
ation inhibitors of BCR-ABL for the treat-
ment of imatinib-resistant chronic myeloid
leukaemia. Nat Rev Cancer. 2007; 7(5):345-
56.
6. Weisberg E, Manley PW, Breitenstein W,
Bruggen J, Cowan-Jacob SW, Ray A, et al.
Characterization of AMN107, a selective
inhibitor of native and mutant Bcr-Abl.
Cancer Cell. 2005;7(2):129-41.
7. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-
Ibarz JA, Larson RA, Gattermann N, et al.
Nilotinib is effective in patients with chronic
myeloid leukemia in chronic phase following
imatinib resistance or intolerance: 24-month
follow-up results. Blood. 2011;117(4):1141-5.
8. le Coutre P, Ottmann OG, Giles F, Kim DW,
Cortes J, Gattermann N, et al. Nilotinib (for-
merly AMN107), a highly selective BCR-ABL
tyrosine kinase inhibitor, is active in patients
with imatinib-resistant or -intolerant acceler-
ated-phase chronic myelogenous leukemia.
Blood. 2008;111(4):1834-9.
9. Saglio G, Kim DW, Issaragrisil S, le Coutre P,
Etienne G, Lobo C, et al. Nilotinib versus
imatinib for newly diagnosed chronic
myeloid leukemia. N Engl J Med. 2010;362
(24):2251-9.
10. Center for Drug Evaluation and Research:
Nilotinib Pharmacology/Toxicology Review
and Evaluation, 2007.
11. Wolf A, Couttet P, Dong M, Grenet O, Heron
M, Junker U, et al. Preclinical evaluation of
potential nilotinib cardiotoxicity. Leuk Res.
2011;35(5):631-7.
12. Kantarjian H, Giles F, Wunderle L, Bhalla K,
O'Brien S, Wassmann B, et al. Nilotinib in
imatinib-resistant CML and Philadelphia
chromosome-positive ALL. N Engl J Med.
2006;354(24):2542-51.
13. Schwartz PJ, Moss AJ, Vincent GM,
Crampton RS. Diagnostic criteria for the long
QT syndrome. An update. Circulation.
1993;88(2):782-4.
14. Task Force for Diagnosis and Treatment of
Non-ST-Segment Elevation Acute Coronary
Syndromes of European Society of
Cardiology, Bassand JP, Hamm CW,
Ardissino D, Boersma E, et al. Guidelines for
the diagnosis and treatment of non-ST-
segment elevation acute coronary syn-
dromes. Eur Heart J. 2007;28(13):1598-660.
15. Van de Werf F, Bax J, Betriu A, Blomstrom-
Lundqvist C, Crea F, Falk V, et al.
Management of acute myocardial infarction
in patients presenting with persistent ST-seg-
ment elevation: the Task Force on the
Management of ST-Segment Elevation Acute
Myocardial Infarction of the European
Society of Cardiology. Eur Heart J.
2008;29(23):2909-45.
16. Albini A, Pennesi G, Donatelli F, Cammarota
R, De Flora S, Noonan DM. Cardiotoxicity of
anticancer drugs: the need for cardio-oncolo-
gy and cardio-oncological prevention. J Natl
Cancer Inst. 2010;102(1):14-25.
17. Monsuez JJ, Charniot JC, Vignat N, Artigou
JY. Cardiac side-effects of cancer chemother-
apy. Int J Cardiol. 2010;144(1):3-15.
18. Yeh ET, Bickford CL. Cardiovascular compli-
cations of cancer therapy: incidence, patho-
genesis, diagnosis, and management. J Am
Coll Cardiol. 2009;53(24):2231-47.
19. Cheng H, Force T. Molecular mechanisms of
cardiovascular toxicity of targeted cancer
therapeutics. Circ Res. 2010;106(1):21-34.
20. Force T, Krause DS, Van Etten RA. Molecular
mechanisms of cardiotoxicity of tyrosine
kinase inhibition. Nat Rev Cancer.
2007;7(5):332-44.
21. Orphanos GS, Ioannidis GN, Ardavanis AG.
Cardiotoxicity induced by tyrosine kinase
inhibitors. Acta Oncol. 2009;48(7):964-70.
22. Hasinoff BB, Patel D. The lack of target speci-
ficity of small molecule anticancer kinase
inhibitors is correlated with their ability to
damage myocytes in vitro. Toxicol Appl
Pharmacol. 2010;249(2):132-9.
23. Chu TF, Rupnick MA, Kerkela R, Dallabrida
SM, Zurakowski D, Nguyen L, et al.
Cardiotoxicity associated with tyrosine
kinase inhibitor sunitinib. Lancet.
2007;370(9604):2011-9.
24. Schmidinger M, Zielinski CC, Vogl UM,
Bojic A, Bojic M, Schukro C, et al. Cardiac
toxicity of sunitinib and sorafenib in patients
with metastatic renal cell carcinoma. J Clin
Oncol. 2008;26(32):5204-12.
25. Kerkela R, Grazette L, Yacobi R, Iliescu C,
Patten R, Beahm C, et al. Cardiotoxicity of
the cancer therapeutic agent imatinib mesy-
late. Nat Med. 2006;12(8):908-16.
26. Atallah E, Durand JB, Kantarjian H, Cortes J.
Congestive heart failure is a rare event in
patients receiving imatinib therapy. Blood.
2007;110(4):1233-7.
27. Estabragh ZR, Knight K, Watmough SJ,
Lane S, Vinjamuri S, Hart G, et al. A
prospective evaluation of cardiac function
in patients with chronic myeloid leukaemia
treated with imatinib. Leuk Res. 2011;35(1):
49-51.
28. Marcolino MS, Ribeiro AL, Clementino NC,
Nunes Mdo C, Barbosa MM, Silva MH, et al.
The use of imatinib mesylate has no adverse
effects on the heart function. Results of a
pilot study in patients with chronic myeloid
leukemia. Leuk Res. 2011;35(3):317-22.
29. Perik PJ, Rikhof B, de Jong FA, Verweij J,
Gietema JA, van der Graaf WT. Results of
plasma N-terminal pro B-type natriuretic
peptide and cardiac troponin monitoring in
GIST patients do not support the existence
of imatinib-induced cardiotoxicity. Ann
Oncol. 2008;19(2):359-61.
30. Ribeiro AL, Marcolino MS, Bittencourt HN,
Barbosa MM, Nunes Mdo C, Xavier VF, et al.
An evaluation of the cardiotoxicity of ima-
tinib mesylate. Leuk Res. 2008;32(12):1809-
14.
31. Tiribelli M, Colatutto A, Marin L, Barbina G,
Qualizza U, Damiani D, et al. Brain natri-
uretic peptide level as marker of cardiac func-
tion in imatinib--treated chronic myeloid
leukemia patients: no evidence of cardiotox-
icity of imatinib therapy. Am J Hematol.
2008;83(6):517-8.
32. Turrisi G, Montagnani F, Grotti S, Marinozzi
C, Bolognese L, Fiorentini G. Congestive
heart failure during imatinib mesylate treat-
ment. Int J Cardiol. 2010;145(1):148-50.
33. Verweij J, Casali PG, Kotasek D, Le Cesne A,
Reichard P, Judson IR, et al. Imatinib does not
induce cardiac left ventricular failure in gas-
trointestinal stromal tumours patients: analy-
sis of EORTC-ISG-AGITG study 62005. Eur
J Cancer. 2007;43(6):974-8.
34. Fernandez A, Sanguino A, Peng Z, Ozturk E,
Chen J, Crespo A, et al. An anticancer C-Kit
kinase inhibitor is reengineered to make it
more active and less cardiotoxic. J Clin
Invest. 2007;117(12):4044-54.
35. Kantarjian H, Shah NP, Hochhaus A, Cortes
J, Shah S, Ayala M, et al. Dasatinib versus
imatinib in newly diagnosed chronic-phase
chronic myeloid leukemia. N Engl J Med.
2010;362(24):2260-70.
36. Aichberger KJ, Herndlhofer S, Schernthaner
GH, Schillinger M, Mitterbauer-
Hohendanner G, Sillaber C, et al.
Progressive peripheral arterial occlusive dis-
ease and other vascular events during nilo-
tinib therapy in CML. Am J Hematol. 2011;
86(7):533-9.
37. Kantarjian HM, Hochhaus A, Saglio G, De
Souza C, Flinn IW, Stenke L, et al. Nilotinib
versus imatinib for the treatment of patients
with newly diagnosed chronic phase,
Philadelphia chromosome-positive, chronic
myeloid leukaemia: 24-month minimum fol-
low-up of the phase 3 randomised ENESTnd
trial. Lancet Oncol. 2011;12(9):841-51.
38. Le Coutre P, Rea D, Abruzzese E, Dombret
H, Trawinska MM, Herndlhofer S, et al.
Severe peripheral arterial disease during nilo-
tinib therapy. J Natl Cancer Inst. 2011;103
(17):1347-8.
39. NeLM news service: Healthcare professional
communication regarding association of
dasatinib (Sprycel®) with pulmonary arterial
hypertension. 2011.
40. Strevel EL, Ing DJ, Siu LL. Molecularly target-
ed oncology therapeutics and prolongation
of the QT interval. J Clin Oncol. 2007;25
(22):3362-71.
41. Haverkamp W, Breithardt G, Camm AJ,
Janse MJ, Rosen MR, Antzelevitch C, et al.
The potential for QT prolongation and proar-
rhythmia by non-antiarrhythmic drugs: clin-
ical and regulatory implications. Report on a
policy conference of the European Society of
Cardiology. Eur Heart J. 2000;21 (15):1216-
31.
42. Priori SG, Schwartz PJ, Napolitano C, Bloise
R, Ronchetti E, Grillo M, et al. Risk stratifica-
tion in the long-QT syndrome. N Engl J Med.
2003;348(19):1866-74.
43. Sauer AJ, Moss AJ, McNitt S, Peterson DR,
Zareba W, Robinson JL, et al. Long QT syn-
drome in adults. J Am Coll Cardiol. 2007;
49(3):329-37.
44. Altena R, Perik PJ, van Veldhuisen DJ, de
Vries EG, Gietema JA. Cardiovascular toxici-
ty caused by cancer treatment: strategies for
early detection. Lancet Oncol. 2009;10(4):
391-9.
45. Valent P. Severe adverse events associated
with the use of second-line BCR/ABL tyro-
sine kinase inhibitors: preferential occurrence
in patients with comorbidities.
Haematologica. 2011;96(10):1395-7.
46. Dolci A, Dominici R, Cardinale D, Sandri
MT, Panteghini M. Biochemical markers for
prediction of chemotherapy-induced car-
diotoxicity: systematic review of the litera-
ture and recommendations for use. Am J Clin
Pathol. 2008;130(5):688-95.
47. Jabbour E, Hochhaus A, Cortes J, La Rosee P,
Kantarjian HM. Choosing the best treatment
strategy for chronic myeloid leukemia
patients resistant to imatinib: weighing the
efficacy and safety of individual drugs with
BCR-ABL mutations and patient history.
Leukemia. 2010;24(1):6-12.
48. Mahon FX, Rea D, Guilhot J, Guilhot F,
Huguet F, Nicolini F, et al. Discontinuation of
imatinib in patients with chronic myeloid
leukaemia who have maintained complete
molecular remission for at least 2 years: the
prospective, multicentre Stop Imatinib
(STIM) trial. Lancet Oncol. 2010;11(11):1029-
35.
49. Rea D, Rousselot P, Nicolini FE, Legros L,
Tulliez M, Giraudier S, et al. Discontinuation
of dasatinib or nilotinib in chronic myeloid
leukemia (CML) patients (pts) with stable
undetectable Bcr-Abl transcripts: results from
the French CML Group (FILMC). ASH
Annual Meeting Abstracts. 2011;118(21):604.
Cardiac safety of nilotinib
haematologica | 2012; 97(6) 889
